Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.32 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587327 | 0.98 | ALDH1A1 (0.34) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL13587329 | 0.81 | PDE7A (0.36) | PNPHPRT1 | |
| SCHEMBL13587326 | 0.79 | PNP (0.38) | PNPHPRT1 | |
| SCHEMBL13587322 | 0.79 | ADORA2A (0.45) | CYP1A2ADORA3 | |
| SCHEMBL13587323 | 0.76 | ADORA2A (0.47) | CYP1A2ADORA3 | |
| SCHEMBL13587321 | 0.74 | GRM5 (0.30) | GRM5 | |
| SCHEMBL13587316 | 0.72 | IP6K1 (0.45) | ALDH1A1LMNAMAPK1GRM5ADORA3 | |
| SCHEMBL13587319 | 0.71 | GRM5 (0.31) | GRM5CREBBP | |
| SCHEMBL13587320 | 0.69 | IP6K1 (0.37) | ALDH1A1LMNAMAPK1PNPHPRT1 | |
| SCHEMBL13587330 | 0.68 | IP6K1 (0.39) | ALDH1A1MAPK1PNPHPRT1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299049-A1 | Bicyclic Compounds and Their Use | REPLIZYME LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299049-A1 | Bicyclic Compounds and Their Use | ERCC4, PARP1, ERCC5 | ALDH1A1 1108/4885LMNA 93/4885ALB 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.